X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DIVIS LABORATORIES - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DIVIS LABORATORIES SANOFI INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 32.8 31.3 104.8% View Chart
P/BV x 6.2 5.4 115.3% View Chart
Dividend Yield % 1.4 0.9 158.0%  

Financials

 SANOFI INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
DIVIS LABORATORIES
Mar-17
SANOFI INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs4,5601,222 373.2%   
Low Rs4,400784 561.2%   
Sales per share (Unadj.) Rs1,028.5153.1 671.8%  
Earnings per share (Unadj.) Rs129.039.9 322.8%  
Cash flow per share (Unadj.) Rs186.044.6 417.1%  
Dividends per share (Unadj.) Rs68.0010.00 680.0%  
Dividend yield (eoy) %1.51.0 152.2%  
Book value per share (Unadj.) Rs753.6201.8 373.4%  
Shares outstanding (eoy) m23.03265.47 8.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.6 66.5%   
Avg P/E ratio x34.725.1 138.3%  
P/CF ratio (eoy) x24.122.5 107.1%  
Price / Book Value ratio x5.95.0 119.6%  
Dividend payout %52.725.0 210.6%   
Avg Mkt Cap Rs m103,174266,266 38.7%   
No. of employees `0003.69.7 37.2%   
Total wages/salary Rs m3,5924,687 76.6%   
Avg. sales/employee Rs Th6,537.74,175.0 156.6%   
Avg. wages/employee Rs Th991.4481.5 205.9%   
Avg. net profit/employee Rs Th819.81,089.3 75.3%   
INCOME DATA
Net Sales Rs m23,68640,643 58.3%  
Other income Rs m708749 94.5%   
Total revenues Rs m24,39441,392 58.9%   
Gross profit Rs m5,28114,460 36.5%  
Depreciation Rs m1,3131,233 106.5%   
Interest Rs m1523 66.4%   
Profit before tax Rs m4,66113,953 33.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6913,349 50.5%   
Profit after tax Rs m2,97010,604 28.0%  
Gross profit margin %22.335.6 62.7%  
Effective tax rate %36.324.0 151.1%   
Net profit margin %12.526.1 48.1%  
BALANCE SHEET DATA
Current assets Rs m15,67340,105 39.1%   
Current liabilities Rs m6,6786,595 101.3%   
Net working cap to sales %38.082.5 46.1%  
Current ratio x2.36.1 38.6%  
Inventory Days Days76119 64.1%  
Debtors Days Days2281 27.7%  
Net fixed assets Rs m8,09819,995 40.5%   
Share capital Rs m230531 43.4%   
"Free" reserves Rs m17,08853,043 32.2%   
Net worth Rs m17,35653,574 32.4%   
Long term debt Rs m00-   
Total assets Rs m25,40061,585 41.2%  
Interest coverage x311.7618.4 50.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.7 141.3%   
Return on assets %11.817.3 68.1%  
Return on equity %17.119.8 86.5%  
Return on capital %26.926.1 103.3%  
Exports to sales %24.50-   
Imports to sales %28.025.2 110.8%   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,62710,259 64.6%   
Fx inflow Rs m7,14535,384 20.2%   
Fx outflow Rs m6,84610,399 65.8%   
Net fx Rs m29924,985 1.2%   
CASH FLOW
From Operations Rs m3,22611,493 28.1%  
From Investments Rs m-1,555-11,372 13.7%  
From Financial Activity Rs m-1,818-93 1,952.7%  
Net Cashflow Rs m-14728 -517.6%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 11.8 122.0%  
FIIs % 14.6 19.0 76.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.2 61.0%  
Shareholders   15,184 31,796 47.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   SUVEN LIFE  DISHMAN PHARMA  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 300 Points; Tata Steel Up 3.5%(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading near all-time high levels. Sectoral indices are trading on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jan 23, 2018 01:35 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS